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Are pulmonary hemostasis and fibrinolysis out of balance in 
equine chronic pneumopathies?
Ann Kristin Barton1,*, Caroline Wirth1, Angelika Bondzio2, Ralf Einspanier2, Heidrun Gehlen1
1Equine Clinic, and 2Institute of Veterinary Biochemistry, Freie Universitaet Berlin, 14163 Berlin, Germany
Clinical examination, bronchoalveolar lavage fluid (BALF) cytology, acute-phase protein, and pulmonary hemostasis and fibrinolysis marker 
(fibrinogen, serum amyloid A [SAA], and D-dimer) results were compared between control and respiratory disease-affected horses. Using 
a clinical scoring system, horses (n = 58) were classified as respiratory disease-free (Controls, n = 15) or with recurrent airway obstruction 
(RAO; n = 18), inflammatory airway disease (n = 14) or chronic interstitial pneumopathy (n = 11). There were no significant differences in 
fibrinogen concentrations among groups, but there was a trend toward a lower value in controls (median 0.0024 g/L) than in horses with chronic 
pneumopathies (median 0.0052 g/L), in particular, those with RAO (median 0.0062 g/L). Fibrinogen concentration was positively correlated 
with percentage of neutrophils in BALF (rs = 0.377, p = 0.004). SAA concentrations were low; 65.5% of samples were below the detection 
limit. D-dimer concentrations were also low and quantifiable concentrations were only obtained after ultrafiltration and only in RAO (median 
0.1 mg/L). In conclusion, there was limited evidence of increased coagulatory activity in chronic pneumopathies, apart from RAO. It is 
uncertain whether fibrinogen and D-dimer concentrations increased due to their role as acute-phase proteins or as a misbalance of coagulation 
and fibrinolysis.
Keywords: chronic interstitial pneumopathy, horses, inflammatory airway disease, inflammatory biomarker, recurrent airway 
obstruction
Introduction
While numerous studies have demonstrated a misbalance of 
pulmonary hemostasis and fibrinolysis in various forms of 
pulmonary disease in humans, little related data has been 
reported for the horse. Respiratory diseases, in particular, 
recurrent airway obstruction (RAO) and inflammatory airway 
disease (IAD), affect a large number of racing and performance 
horses and may cause exercise insufficiency; therefore, such 
diseases can have a high impact on the career of a sport horse. 
In chronic pulmonary disease, remodeling results in a decreased 
airway lumen, increased smooth muscle mass, peribronchial 
fibrosis, epithelial cell hyperplasia, and impaired airway 
function [24,27]. Fibrosis formation is the ultimate result of a 
misbalance between pulmonary hemostasis and fibrinolysis, 
which is the result of procoagulatory factors favoring hemostasis, 
downregulation of fibrinolysis, or a combination of both. 
Regulation of remodeling may be critical for developing new 
therapeutics and managing respiratory diseases [26].
Previous authors [17,18] have reported that the cell-free 
supernatant of respiratory secretions from horses affected by 
RAO may induce coagulation of plasma. This procoagulatory 
activity was associated with the severity of the respiratory 
disease and the neutrophil percentages in tracheobronchial 
aspirate (TBA) and bronchoalveolar lavage fluid (BALF). As 
shown for various forms of pulmonary disease in humans 
[19,21,40], in the horse, the procoagulatory state is a result of 
increased tissue factor–factor VII complex activity [17,18] and, 
therefore, the extrinsic coagulation pathway.
Fibrin and its derivation products may have a central role in 
equine pulmonary disease. Increases in soluble fibrinogen 
derivates are present in the majority of cell-free supernatants of 
respiratory secretions from horses suffering from chronic 
pneumopathies, which again is associated with neutrophil 
percentages and severity of disease [45]. Based on 
immunohistochemical analysis, fibrin and fibrinogen were 
observed in TBAs and in histologic preparations of thickened 
alveolar septae and bronchial mucus accumulations. These 
results were observed in cases of RAO as well as in cases with 
chronic broncho-interstitial and granulomatous interstitial 
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pneumopathies [45].
Although not directly coagulation and fibrinolysis associated, 
serum amyloid A (SAA) was also evaluated as part of the 
present study. As fibrinogen is not only a product of coagulation 
but is also an acute-phase protein, we decided to evaluate SAA 
as it is another parameter known for its sensitivity to inflammatory 
processes [23,25,34]. SAA has been reported to be involved in 
pulmonary inflammation in humans, and increased SAA 
concentrations are present in asthma and chronic obstructive 
pulmonary disease (COPD) [1,2,30,32]. In addition, reported 
increased SAA concentrations in plasma of horses affected by 
RAO. To our knowledge, SAA has not been evaluated in equine 
BALF.
In addition, there are no reports of studies focusing on equine 
pulmonary fibrinolysis, although some information is available 
for other organ systems. In colic, sepsis, and septic and non-septic 
arthritis, there is evidence of alterations in coagulation. Moreover, 
changes in fibrinolysis have been reported in humans 
[3,8,29,36]. The affected parameters may be measured 
systemically in plasma, but local changes in fluids from affected 
body cavities can be even more pronounced, such as in the 
peritoneal fluid of horses with colic or synovia in septic and 
non-septic arthritis [9,11,35]. Therefore, in the present study, 
we examined BALF to compare markers of hemostasis and 
fibrinolysis in different equine chronic pneumopathies.
In dogs, pulmonary fibrinolysis associated with micro 
thromboembolism caused by heartworm infection has been 
studied, and the results showed that D-dimer deposits in lungs 
and kidneys and increased plasma values of D-dimers were 
associated with pulmonary thromboembolism and microfilaremic 
status [5].
A study in cats investigated the effects on lungs of inhibiting 
the fibrinolytic system by using tranexamic acid. Inhibition of 
the fibrinolytic system appears to have initiated emphysematous 
alterations, alveolar wall destruction, and collagen accumulation 
possibly by causing microthromboses leading to mechanical 
blockage and ischemic changes, or by causing secondary 
fibrinolysis as a result of fibrin degradation products affecting 
local plasminogen activators and proteases. An injury-repair 
process also appears to have occurred [20].
Pulmonary hemostasis and fibrinolysis has been studied 
extensively in mice, and mouse models have been used for 
research focusing on human asthma and COPD. In mouse, 
proteins of the hemostasis and fibrinolysis systems have been 
shown to be involved in the pathomechanisms related to airway 
hypersensitivity. After inhalation of an aerosol containing 
fibrinogen and followed by thrombin, mice were found to be 
hypersensitive in a methacholine provocation test compared to 
the sensitivity in mice after inhalation of saline [44]. The 
presence of thrombin, fibrinogen, and fibrin in the airways of 
asthmatic subjects indicates inhibition of fibrinolysis as well as 
increased hemostatic activity [33,44]. Yuda et al. [46] found 
increased thrombin and soluble tissue factor levels in BALF of 
exacerbated mice after ovalbumin challenge. Treatment with 
anticoagulant protein C inhibited the type 2 T helper cells 
mediated immune response and airway obstruction.
Coagulation factor Xa has a central role in pulmonary 
remodeling. Increased concentrations of factor Xa mRNA have 
been observed in pulmonary tissue and BALF of mice after 
allergen challenge, and the application of a factor Xa inhibitor 
has resulted in decreased respiratory mucosa thickness and 
collagen deposition in pulmonary tissue. Factor Xa-dependent 
mucin production has also been reported [39].
The aim of this study was to compare clinical and cytological 
data with fibrinogen, SAA, plasminogen activator inhibitor-1 
(PAI-1), and D-dimer concentrations between healthy horses 
and different groups of horses with chronic pneumopathy 
including horses with RAO, IAD, and chronic interstitial 
pneumopathy (CIP). The study was undertaken to evaluate the 
possibility of a misbalance between the two branches of 
hemostasis: coagulation and fibrinolysis.
Materials and Methods
Preparticipation examination
Horses were examined for 3 successive days from the day of 
admission until date of discharge. A total of 61 horses (height 
154 ± 12 cm, age 12 ± 5 years, bodyweight 469 ± 96 kg) were 
examined, of which 15 had no clinical signs or history of 
respiratory disease (controls) and 46 had presented to the 
Equine Clinic of the Free University of Berlin with a history of 
chronic lower airway disease. Sampling of horses affected by 
respiratory disease was not classified as animal experimentation 
by the State Office of Health and Social Affairs Berlin, but 
sampling of control horses was approved by that group 
(reference No. L0294/13). In addition, owners gave permission 
to involve their horses in the study.
A preparticipation examination was performed and included 
clinical examination of the respiratory tract, blood gas analysis, 
endoscopy, and cytology of BALF. A clinical scoring system 
recommended by an international workshop was used (Table 1) 
[15,31,37]. The scoring system was modified by including the 
determination of neutrophil percentages in BALF instead of 
TBAs.
The experimental groups were established as follows: (1) 
Control group, no history of respiratory disease, clinical score 
＜ 2, no tracheal secretions, low cellular density and neutrophils 
≤ 10% in BALF, alveolar–arterial gradient (AaDO2) ≤ 7 
mmHg, and exclusion of acute signs of infection (leukocytosis, 
fever, depression); (2) RAO group, history of recurrent cough 
or dyspnea, clinical score ＞ 6, high amount or viscosity of 
tracheal secretion, high cellular density and neutrophils ≥ 25% 
in BALF, AaDO2 ＞ 7 mmHg, and exclusion of acute signs of 
infection (leukocytosis, fever, depression), as previously described 
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Table 1. Clinical scoring system*
Score Maximum points
Coughing No cough after manual compression of larynx 0 1
Coughing during manual larynx compression 1
Very frequent coughing 1
Spontaneous coughing 1
Dyspnea at rest Prolonged expiration 1 3
Abdominal breathing 1




Lung percussion ＜ 3 fingers enlargement of lung field 0 2
＜ Handbreadth enlargement of lung field 1
＞ Handbreadth enlargement of lung field 2
Lung auscultation Rattling 2 2
Crackle 2
Wheezing 2
Respiratory endoscopy Significantly increased secretions with moderate viscosity 1 2
Highly increased secretions with high viscosity 2
Thickened carina of the trachea 1
BALF cytology Neutrophils ＜ 10% 0 3
Neutrophils 10–15% 1
Neutrophils 16–25% 2
Neutrophils ＞ 25% 3
Arterial blood gas analysis AaDo2: 0–7 mmHg 0 2
AaDo2: 7–14 mmHg 1
AaDo2: ＞ 14 mmHg 2
*The system modified from Ohnesorge [31] was used in this study andwas modified by assessing neutrophils in bronchoalveolar lavage fluid (BALF) rather 
than in tracheal aspirates.
[37]. (3) IAD group, history of cough or exercise insufficiency, 
clinical score 2–6, low to moderate amount or viscosity of 
tracheal secretions, increased cellular density and neutrophils 
≥ 10% or mast cells ≥ 2% or eosinophils ≥ 0.1% in BALF, 
AaDO2 ＞ 7 mmHg, and exclusion of acute signs of infection 
(leukocytosis, fever, depression), as previously described [10]; 
and (4) CIP group, history of exercise insufficiency, clinical 
score 2–6, low to moderate amount or viscosity of tracheal 
secretions, increased cellular density and ratio of macrophages 
to neutrophils ≥ 2.6:1 in BALF, increased interstitial opacity of 
thoracic radiographs, and exclusion of acute signs of infection 
(leukocytosis, fever, depression), as previously described [12].
BALF collection and processing
Following endoscopy, 20 mL of 2% lidocaine (bela-pharm, 
Germany) were infused around the carina of the trachea. 
Bronchoalveolar lavage (BAL) was performed by using a 300 
cm silicone BAL catheter (Smiths Medical, USA), which was 
passed nasally into the distal respiratory tract and wedged into 
the bronchus by expansion of an air balloon. Five hundred 
milliliters of pre-warmed phosphate buffered saline (Lonza, 
Belgium) were infused into the bronchi through a BAL catheter 
as recommended by the International Workshop on Equine 
Chronic Airway Disease [37] and immediately aspirated.
After aspiration, the recovered sample volume was recorded 
and divided into two portions, one for cytological examination 
and the second for biochemical analysis. For cytological 
examination, the samples were centrifuged at 250 × g for 10 
min, then a direct smear was obtained, air-dried, stained by 
using the May-Grünwald Giemsa method (Sigma-Aldrich 
Germany), and 500 cells were examined via oil immersion 
microscopy at 1,000 × magnification. For biochemical analysis, 
BALF was centrifuged in a table top refrigerated centrifuge 
(Hermle Z326K; HERMLE Labortechnik, Germany) at 250 × g 
for 10 min at 4oC. The cell-free supernatant was collected and 
stored at −80oC until assayed. Samples were transported to 
external laboratories on dry ice.
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Table 2. Results of clinical examinations presented as means ± SD
Control (n = 15) RAO (n = 18) IAD (n = 14) CIP (n = 11)
Dyspnea 0 ± 0 1.61 ± 1.0* 0.07 ± 0.27 0.36 ± 0.92
Lung auscultation 0 ± 0 0.35 ± 0.78 0.22 ± 0.65 0 ± 0
Endoscopy 0 ± 0 1.78 ± 0.43* 1.14 ±0.66* 0.91 ± 0.7*
BALF cytology 0 ± 0 3 ± 0* 1.57 ±1.02* 0.45 ± 0.69
Blood gas analysis 0.27 ± 0.4 0.78 ± 0.73* 0.14 ± 0.36 0.36 ± 0.81
Total exam score 0.33 ± 0.46 8.12 ± 2.17* 3.36 ± 1.27*   2.45 ± 2.73*
RAO, recurrent airway obstruction; IAD, inflammatory airway disease; CIP, chronich interstitial pneumopathy. *Significant difference (p ＜ 0.05) from the 
control value.
Table 3. Bronchoalveolar lavage fluid cytology results
Controls (n = 15) RAO (n = 18) IAD (n = 14) CIP (n = 11)
Macrophages (%)      58 (53.7/59.8)   17.3 (8.3/28.3)* 49.5 (30.7/52.5)    54 (40/62.8)
Lymphocytes (%)   37.4 (32.8/42.7)   17.6 (6.9/30.2)* 30.5 (24.4/38.5) 33.4 (23.2/40)
Neutrophils (%)    2 (1.2/4.6)     51.4 (45.1/84.8)*   16.4 (11.9/22.6)* 7.2 (5.8/10)
Eosinophils (%) 0 (0/0.2) 0 (0/0.5) 0 (0/1.3)  1 (0/1.8)
Mast cells (%) 1.6 (1.2/2.6)    1 (0.1/1.6) 3.1 (0.9/4.7) 3.4 (2/7.2)
Cell percentages are expressed as medians (min/max). RAO, recurrent airway obstruction; IAD, inflammatory airway disease; CIP, chronich interstitial 
pneumopathy. *Significant difference (p ＜ 0.05) from the control value.
Group classification
Based on the results of the preparticipation examinations, the 
61 horses presented for participation in this study were grouped 
as follows: Control group, 15 horses (24.5%); RAO group, 18 
(29.5%) horses; IAD group, 14 (23.0%) horses; and CIP group, 
11 (18.0%) horses. Three horses (5.0%) suffered from acute 
respiratory infection and were excluded from the study. Among 
the remaining 58 horses, there were insignificant differences in 
the severity of dyspnea, amount and viscosity of tracheal 
secretions, and AaDO2 estimates among the disease groups. 
The overall results of the clinical examinations are presented in 
Table 2. Percentages of macrophages, lymphocytes, mast cells, 
and neutrophils were similar among the groups, except for 
significant differences between the control and RAO groups in 
macrocyte, lymphocyte, and neutrophil percentages and 
between control and IAD groups in neutrophil percentages 
(Table 3). 
Evaluation of fibrinogen
Fibrinogen concentrations in the 58 horses were measured in 
samples of BALF supernatant by using automatized immune 
turbidimetry (C701 module, Cobas 8000 series; Roche 
Diagnostics, Germany). The specific limit of fibrinogen detection 
was 0.001 g/L.
Evaluation of SAA
SAA was evaluated in BALF supernatant samples from 58 
horses by using a multispecies sandwich enzyme-linked 
immunosorbent assay (ELISA) kit (Phase SAA Assay; Tridelta 
Development, Ireland). All BALF supernatant samples were 
tested undiluted and the limit of SAA detection was 0.01 
g/mL. 
Evaluation of D-dimers
D-dimer concentrations in BALF supernatant were measured 
in samples from 58 horses by using an automatized analyzer 
(Sysmex CA-1500 system; Sysmex, Germany) and performing 
immune turbidimetry (INNOVANCE D-dimer test; Siemens 
Healthcare Diagnostics, Germany). The limit of D-dimer 
detection was 0.19 mg/L fibrinogen equivalent units. As most 
samples were below the limit of detection, 3 samples from 
control horses and 18 samples from RAO horses were concentrated 
by ultrafiltration at 2,000 × g for 60 min by using a Rotina 420R 
centrifuge (Andreas Hettich, Germany).
Evaluation of PAI-1
For PAI-1 measurements, three ELISA kits from different 
manufacturers were used a competitive ELISA kit (Horse 
Plasminogen Activator Inhibitor 1 ELISA Kit, Cusabio 
Biotech, USA), a sandwich ELISA kit with equine antibodies 
(Nori Equine Serpin E1/PAI-1 ELISA, Genorise Scientific, 
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Fig. 1. Fibrinogen concentrations among the four disease groups.
Although no significant differences were found, there was a 
trend toward a lower value in control horses (median 0.0024 g/L)
than in horses with RAO (median 0.0062 g/L). RAO, recurrent 
airway obstruction; IAD, inflammatory airway disease; CIP, 
chronich interstitial pneumopathy. 
Fig. 2. Correlation between fibrinogen concentration and 
percentage of neutrophils in BALF for all horses included in the
study. RAO, recurrent airway obstruction; IAD, inflammatory 
airway disease; CIP, chronich interstitial pneumopathy.
USA), and a human ELISA kit (Quantikine ELISA, Human 
Serpin E1/PAI-1; R&D Systems, USA). All kits were tested for 
their suitability for measuring PAI-1 in equine BALF.
Statistical analysis
Data were statistically analyzed and graphically presented by 
using SPSS Statistics (ver. 22.0 SPSS Campus Edition; IBM, 
USA). The data were tested for normal distributions by using 
the Kolmogorov-Smirnov and Shapiro Wilks tests and are 
expressed as mean ± SD values for normally distributed data 
and as median and 25%/75% quartiles for non-normally distributed 
data. The level of significance was set at p ˂ 0.05. Kruskal 
Wallis H testing followed by post hoc testing using the Dunnett’s 
test was used to compare the control group results with those of 
the different disease groups.
Results
Assays for the quantification of fibrinogen, SAA, D-dimer, 
and PAI-1 concentrations were performed in BALF supernatant 
obtained from 58 horses. The results are summarized as 
follows.
Fibrinogen
Concentrations of samples below the limit of detection at 
0.001 g/L were defined as 0.0005 g/L for statistical analysis 
purposes. Although no significant differences were found 
between disease groups (Fig. 1), descriptive data analysis showed 
a trend toward a lower value in the control group (median 
0.0024 g/L) than those in the combined chronic pneumopathy 
groups (RAO, IAD, and CIP; median 0.0052 g/L) and, in 
particular, lower than that in the RAO group (median 0.0062 
g/L). Forty percent of the control samples were below the limit 
of detection, while among the combined chronic pneumopathies 
only 16% were below the limit of detection; percentages below 
the limit of detection were 5.6%, 21.4%, and 27.7% in the RAO, 
IAD, and CIP groups, respectively. The individual fibrinogen 
concentrations in the 58 horses were positively correlated with 
their percentage of neutrophils in BALF (rs = 0.377, p = 0.004) 
(Fig. 2).
SAA
Sample SAA concentrations that were below the limit of 
detection (0.01 g/mL) were defined as 0.005 g/mL for 
statistical analysis purposes. Overall, the SAA concentrations 
were notably low and in the majority of samples (65.5%) were 
below the limit of detection. No significant differences were 
found between the control group and the combined chronic 
pneumopathies group or each of the individual disease groups.
D-dimers
Immune turbidimetric analysis of D-dimers revealed 
concentrations below the test’s specific limit of detection in 
94.8% of samples. The only samples in which concentrations 
could be quantified were from horses in the RAO group. 
Therefore, 18 samples of this group and 3 control samples 
were subjected to ultrafiltration, which yielded quantifiable 
concentrations in all but one of the RAO samples; however, the 
D-dimer concentrations in the control samples remained below 
the limit of detection. The median concentration in the 
ultrafiltrated RAO samples was 0.1 (0.07/0.185) mg/L with a 
range of 0.035 to 0.33 mg/L.
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PAI-1
PAI-1 concentrations were measured by using three types 
of ELISA kits supplied by three different manufacturers. 
Unfortunately, none of the assays produced reliable standard 
curves or quantifiable results in plasma or BALF samples. 
Therefore, no results were available for statistical analysis.
Discussion 
The aim of this study was to characterize the fibrinolytic 
activity in equine BALF in horses with different chronic 
pneumopathies. Specific activators of fibrinolysis are tissue 
plasminogen activator and urokinase-type plasminogen activator 
(u-PA), while the system is inhibited by plasminogen inhibitors 
(PAI-1 and -2), 2-antiplasmin, and the degradation products of 
fibrinolysis (D-dimers). Several factors need to be evaluated to 
determine whether the system is ultimately activated or 
inhibited. For example, increased D-dimer concentrations 
might lead to the suspicion of increased fibrinolytic activity, but 
increased D-dimer levels may also occur after severe coagulation, 
massive fibrin production, and increased fibrinolysis, indicating 
that the level of D-dimers is insufficient to counteract coagulation 
and may lead to misbalance and, ultimately, hypercoagulation. 
Therefore, it is essential to evaluate other specific regulators of 
the fibrinolytic system as well the D-dimer level. PAI-1 was 
chosen as a parameter of interest in this study, as pulmonary 
fibrinolysis in other species is strongly dependent on u-PA and 
PAI-1 [7,22,38]. PAI-1 concentrations were measured by using 
three types of ELISA, but unfortunately, none of the available 
assays produced reliable standard curves or quantifiable results 
in plasma or BALF samples. Therefore, we focused on 
examining fibrinogen and D-dimer levels and the ratio between 
those two. In a case of overwhelming coagulative activity, a 
high ratio caused by a marked increase in D-dimers might be 
suspected, while a low ratio would be expected in a case of 
overwhelming fibrinolysis. Unfortunately, even after 
ultrafiltration, D-dimer levels could not be quantified in control 
horses, which made comparisons of such ratios among the study 
group impossible; however, after ultrafiltration, D-dimer levels 
could be quantified in horses in the RAO group.
In the present study, the results of fibrinogen concentrations 
are in agreement of those in previous reports, which have shown 
that fibrinogen, an acute-phase protein and a key factor in 
coagulation, is present in TBAs and immune histopathologic 
samples of horses suffering from chronic respiratory disease 
[43,45]. Fibrinogen increases may be explained by increased 
permeability of the capillary endothelium and the alveolar 
epithelium as well as plasma exudation and leakage of plasma 
proteins from the vasculature into the alveolar lumen, features 
that have been reported in humans and suspected in equine 
disease [4,16,43,45]. The positive correlation of fibrinogen 
concentrations with the percentage of neutrophils in BALF 
supports the role of fibrinogen in the pathogenesis of RAO, a 
disease in which neutrophils have a central role as a causative 
agent, or as a consequence of different inflammatory mechanisms 
[14]. This suggestion is supported by the results of Winder et al. 
[45], which showed a correlation of fibrinogen concentration 
and neutrophil percentages in TBAs.
As D-dimer concentrations could only be quantified after 
ultrafiltration and only in samples of horses exhibiting RAO, 
this product of increased coagulation and fibrinolysis may be 
produced in a considerable amount but only in more severe 
inflammatory processes. In this study, D-dimers were not 
produced above the limit of detection in minor stages of 
inflammation, such as in horses with IAD or RAO in remission; 
moreover, they may not be produced to a detectable extent in 
chronic interstitial pneumopathies in which the exudative phase 
of inflammation is over and where fibrosis formation has 
already occurred. Studies in human asthma, a disease resembling 
many features of equine RAO, as well as in acute respiratory 
distress syndrome (ARDS) and pneumonia have reported 
increased D-dimer concentrations in respiratory secretions like 
sputum and BALF [4]. In that study, a clear correlation was 
detected between the grade of inflammation and the D-dimer 
concentration; concentration levels that were in range similar to 
that in our study. Coagulation and fibrinolysis may be triggered 
in the horse by inflammatory stimuli that are minor compared to 
those in humans, as equine RAO has a more chronic nature 
than ARDS or acute pneumonia; regardless, the measured 
concentrations were still similar. Inflammatory processes in 
other organ systems of the horse, such as intestinal disease and 
arthropathies, are associated with notable increases in D-dimers 
[6,13,35,36]. Studies in human and equine arthropathies have 
shown that D-dimer concentrations in synovial fluids compared 
to those in plasma were higher in horses than in humans [36]. 
Moreover, the basal D-dimer value in plasma also seems to be 
higher in horses than in humans [41], therefore, there may be 
species-specific differences in D-dimer production, with horses 
showing more pronounced increases during inflammatory 
processes. Based on the low levels of D-dimers observed in our 
study, more sensitive assays are needed in order to evaluate the 
role of D-dimers in horses with IAD, RAO in remission, or CIP. 
Ultrafiltration was not performed in our IAD and CIP groups as 
all samples were below the limit of detection; nevertheless, if 
undertaken, ultrafiltration may have yielded quantifiable 
concentrations. Ultimately, it cannot be ruled out that D-dimers 
have a more central role in respiratory disease than that revealed 
by our data.
As expected, the results of our study do not support an 
important role of SAA in equine chronic pneumopathies. In the 
majority of samples in our study, SAA was below the limit of 
detection, although significant increases have been observed in 
plasma of horses with severe RAO [25]. It seems logical that 
plasma exudation during inflammation would also lead to 
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leakage of SAA into the alveolar space, but there are several 
reasons that SAA may have remained below the limit of 
detection in our study. First, there is the dilution effect 
associated with BALF. Second, SAA levels can rise quickly, 
and SAA has a short half-life. In the study reported by 
Lavoie-Lamoureux [25], high SAA concentrations were 
measured in plasma at 7 and 30 days after antigen challenge, 
and the SAA levels were easy to quantify. Most horses 
presented for our study had a history of chronic respiratory 
disease and most had not shown acute deterioration of clinical 
signs shortly before examination; therefore, it can be suspected, 
that their SAA concentrations had fallen prior to sampling.
Partly insurmountable weak points of this study were the 
group definitions and assay feasibilities. Although IAD and 
RAO in remission were initially planned as two distinct groups, 
it was not possible to differentiate clearly between the two. The 
available anamnestic information related to respiratory distress 
was often unreliable and the majority of owners did not agree to 
a natural challenge test. Reports describing equine CIP are rare, 
and there is no international consensus statement on CIP 
features; thus, definition of the CIP group was based on a relatively 
old clinical case series of only 12 horses [12]. Thoracic 
radiography showing interstitial patterns have not produced 
very specific results for CIP and some features may also be 
found in RAO and IAD [28,42]. Finally, the majority of owners 
did not agree to lung biopsies. We attempted to reduce these 
problems by calculating correlations between clinical and 
cytological parameters for all 58 horses.
Regarding the assays, typically, one would choose a method 
with the highest sensitivity, thus we principally preferred 
ELISA-based systems, but due to the fact that many of these 
have not been validated for horses, we used other validated or at 
least commonly used assays in our study. A validated ELISA 
assay was available for SAA and has been used in horses 
[25,34], however, many of our SAA samples produced results 
below the limit of detection. For D-dimers, none of the available 
ELISAs provided quantifiable results, thus we undertook 
immunoturbidimetry, and, with ultrafiltration, we were able to 
produce quantifiable concentrations. Fibrinogen was also 
evaluated by using immunoturbidimetry, and that method is 
commonly used in horses and is offered by a commercial 
laboratory. The biggest assay-related quantification problem 
was PAI-1; none of the three assays tested produced reliable 
results even though two species-specific tests were attempted.
In conclusion, this is the first study in which fibrinogen, 
D-dimer, and SAA concentrations were evaluated in BALF of 
healthy horses and compared to horses affected by different 
chronic pneumopathies. Although the aims of the study could 
only be realized in part, the results of the study lead us to suspect 
a misbalance between coagulation and fibrinolysis in respiratory 
disease in horses, with a tendency within that misbalance 
toward fibrin formation. Further studies and improvements in 
assays are essential to further characterize respiratory disease 
pathophysiologic background mechanisms and their influencing 
factors in horses.
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